Quick Facts

• Therapeutic Domain: Addresses acute bleeding episodes
• Patient Population: Individuals with congenital fibrinogen deficiency
• Specific Conditions: Afibrinogenemia and hypofibrinogenemia

---

RiaSTAP is indicated for use in pediatric and adult patients who experience acute bleeding episodes related to a diagnosed congenital fibrinogen deficiency (CFD). The approved therapeutic application focuses on addressing bleeding in individuals with either afibrinogenemia or hypofibrinogenemia, which are specific types of CFD characterized by absent or low levels of fibrinogen protein in the blood.

The core benefit of this medication is to support the body's clotting ability during an active bleeding event. By providing an external source of fibrinogen, the treatment helps facilitate the formation of a stable blood clot, which is necessary to achieve hemostasis. The use is limited to the management of these acute episodes and does not extend to other forms of fibrinogen disorders, such as dysfibrinogenemia.

RiaSTAP (Fibrinogen Concentrate [Human]) is a prescription medicine indicated for the treatment of acute bleeding episodes in pediatric and adult patients diagnosed with congenital fibrinogen deficiency, specifically afibrinogenemia and hypofibrinogenemia.

Populations That Must Not Use RiaSTAP

The medicine is formally contraindicated in patients who have experienced known anaphylactic or severe systemic reactions to RiaSTAP or to any other human plasma-derived product.

Groups Requiring Special Consideration

Use is not indicated for patients with dysfibrinogenemia. The prescribing physician must carefully weigh the potential benefits against the risk of thrombosis in patients with a history of or risk factors for thromboembolic events, such as deep vein thrombosis, pulmonary embolism, myocardial infarction, or arterial thrombosis. This caution applies especially to patients with:

• A history of coronary heart disease or myocardial infarction.
• Underlying liver disease.
• Peri- or post-operative status.
• Neonates.

For pregnant women, there are no available human data; the drug should be used only if clearly needed. The eligibility status for lactating women has not been established.

Interactions with other medicines and products

The official interaction profile for RiaSTAP (Fibrinogen Concentrate, Human) is precisely defined by its nature as a plasma-derived therapeutic protein concentrate, which dictates a focus on procedural compatibility over classical systemic drug-drug interactions. Regulatory documents confirm that no systemic interactions with other medicinal products have been established or are known to occur.

Interaction Profile Summary

Category	Official Regulatory Statement
Systemic Drug Interactions	None known. Official labeling states that no interactions with other medicinal products have been established. This includes the absence of documented pharmacokinetic (e.g., metabolic or transporter) or pharmacodynamic interactions.
Food / Alcohol / Supplements	No specific interactions with food, alcohol, or herbal products are documented in official regulatory sources.
Interaction Restrictions	The only documented constraint is a mandatory procedural compatibility restriction during administration.

Administration Compatibility Constraint

The most critical interaction-related constraint documented in prescribing information is a mandatory physical separation rule applied during intravenous administration. RiaSTAP must not be mixed with any other intravenous solutions or medicinal products in the same container or infusion line. Regulatory information mandates that the product must be administered through a separate, dedicated injection site or infusion line. This administrative constraint ensures the stability and integrity of the protein concentrate, thereby preventing potential physical incompatibility.

How RiaSTAP Works

RiaSTAP's mechanism of action is focused on providing fibrinogen within the final molecular steps of the body's natural coagulation cascade.

Direct Fibrinogen Provision

The primary mechanistic focus involves the direct provision of functional human fibrinogen (Coagulation Factor I) to the circulatory system. This is a form of substrate provision, where the administered product directly integrates into the humoral pathway to provide the precursor protein necessary for fibrin formation. The increased availability of fibrinogen facilitates the progression of reactions through the common pathway.

Activating the Fibrin Cascade

Once introduced, the administered fibrinogen enters the thrombin-mediated fibrin cascade. This is a specific molecular step in which the enzyme thrombin cleaves the fibrinogen molecule, initiating its structural transformation into fibrin monomer. This targeted enzymatic action modifies the molecular steps that shape the systemic physiological processes of hemostasis.

Clot Structure and Polymerization

The final physiological consequence involves fibrin polymerization. Fibrin monomers self-assemble into a structured, mesh-like polymer network. This process is integral to the formation of the structural matrix, resulting in the polymerization of fibrin monomers to form a stable blood clot structure.

Official Administration Guidelines

RiaSTAP (Fibrinogen Concentrate, Human) is exclusively for intravenous (IV) use only, administered directly into a vein. It is supplied as a lyophilized powder in a single-dose vial (potency ranging from 900 mg to 1300 mg) that must be reconstituted with Sterile Water for Injection before use.

Dosing and Frequency

Administration of RiaSTAP is on-demand for acute bleeding episodes and is not part of a fixed, regular schedule. Dosing is highly individualized based on the patient’s clinical status and measured plasma fibrinogen levels. The goal of treatment is to maintain a target fibrinogen level of 100 mg/dL until hemostasis is obtained (bleeding stops).

• If the baseline fibrinogen level is known: The dose is calculated using a formula that factors in the target level, measured level, and body weight.
• If the baseline fibrinogen level is not known: The initial recommended dose is 70 mg per kg of body weight.

Pediatric patients follow the same body-weight-based dosing guidelines as adults.

Preparation and Procedural Constraints

The powder must be gently swirled, not shaken, during reconstitution. The solution must be administered at room temperature by slow intravenous injection at a rate not exceeding 5 mL per minute. The reconstituted solution must be administered through a separate injection site and must not be mixed with other intravenous solutions or medicinal products. Any solution not administered within eight hours of reconstitution must be discarded.

RiaSTAP: Recent Clinical Evidence

---

Research on RiaSTAP (Fibrinogen Concentrate [Human]) focuses primarily on its use in patients with congenital fibrinogen deficiency (also known as afibrinogenemia or hypofibrinogenemia) who are experiencing bleeding or are scheduled for surgery.

Efficacy and Outcome Measurement

Clinical studies have evaluated RiaSTAP's ability to maintain adequate plasma fibrinogen levels in adult and pediatric patients. These studies measure the increase in fibrinogen levels following administration to assess treatment response. A key finding across multiple trials is that the product achieves the pre-specified target fibrinogen trough level in most patients, which is considered necessary for effective hemostasis (stopping bleeding).

Research also involves the use of thrombin generation assays to explore the product's effect on clot formation kinetics.

Use in Bleeding Episodes

Trials evaluating RiaSTAP in the management of acute bleeding episodes (on-demand treatment) for patients with congenital fibrinogen deficiency reported success in achieving hemostatic efficacy—the ability to stop or prevent bleeding. Success was typically defined by the investigator's clinical assessment and observation of the patient's condition.

Safety and Tolerability Profile

As with all human plasma-derived products, post-marketing and clinical data continuously monitor the product's tolerability. The most commonly reported side effects across studies included hypersensitivity reactions, headache, and thrombotic events (blood clots). Due to the potential risk of thromboembolism, its use is carefully assessed in patients with pre-existing risk factors.

Ongoing post-marketing surveillance continues to gather information on the long-term safety and use of RiaSTAP across different age groups and clinical scenarios.

Common questions about RiaSTAP (FAQ)

Q: What is RiaSTAP used for?

According to the official product information, RiaSTAP is a medication approved for the treatment of acute bleeding episodes in people who have congenital fibrinogen deficiency, also known as afibrinogenemia or hypofibrinogenemia. This condition means the body does not have enough of the protein fibrinogen, which is necessary for proper blood clotting.

Q: What type of product is RiaSTAP?

RiaSTAP is classified as a human fibrinogen concentrate. Regulatory documents state it is made from pooled human plasma, and the manufacturing process includes specific steps to reduce the risk of viral transmission.

Q: Where is RiaSTAP administered (e.g., in a hospital, at home)?

Studies and official information indicate that RiaSTAP is administered by intravenous infusion. Administration generally begins in a clinical setting, though official product information notes that administration may occur in the home setting only if directed and supervised by a healthcare professional following proper training.

Q: What is congenital fibrinogen deficiency?

Congenital fibrinogen deficiency is a rare, inherited bleeding disorder where the body cannot produce enough fibrinogen, a vital protein for blood clotting. Official product information indicates that RiaSTAP is used to treat acute bleeding episodes associated with this inherited condition by temporarily replacing the lacking fibrinogen.

Q: How quickly should RiaSTAP be administered?

Official product information provides specific infusion rate guidelines for the intravenous administration of RiaSTAP. The administration rate is defined in the product labeling and is always managed by a qualified healthcare professional, who adjusts it as needed.

Q: Does RiaSTAP contain preservatives?

Regulatory documents state that RiaSTAP does not contain preservatives. The lack of preservatives is a factor that dictates the specific storage and usage guidelines provided in the official product information.

Q: How long can the reconstituted solution be stored before use?

According to the official product information, the reconstituted solution should be used within four hours after mixing. Regulatory handling documents specify that any portion of the mixed solution not used within the four-hour period must be discarded, and the solution should not be placed in the refrigerator during this time.

Storage and Disposal Requirements

The storage and disposal of RiaSTAP must follow specific regulatory requirements for the lyophilized powder and the reconstituted solution.

Storage Conditions

The unopened vial of RiaSTAP powder should be stored in the refrigerator at a temperature between 2 C and 8 C (36 F to 46 F). Storage at room temperature is acceptable, provided the temperature does not exceed 25 C (77 F). The product must be kept in the original carton to protect it from light and must not be frozen.

Product Form	Temperature Range	Stability Constraint
Un-reconstituted Powder	2 C to 25 C	Do not freeze. Keep in original carton.
Reconstituted Solution	20 C to 25 C	Use within 8 hours. Do not refrigerate.

Handling and Disposal

The reconstituted solution is for single-use only and must be administered within 8 hours. Any remaining solution or partially used vials must be discarded. The medicine must always be stored out of the sight and reach of children. All unused product and waste material must be disposed of in accordance with local pharmaceutical waste requirements.